Here are 10 updates on GI companies from the past week.
Pharmaceutical companies Pierre Fabre and Array BioPharma conducted a phase III trial evaluating a triple combination therapy for metastatic colorectal cancer patients, finding the therapy effectively improved progression-free survival rates in 30 patients.
Nebraska medical startup Virtual Incision Corp. completed an $18 million series B round of financing. Virtual Incision developed a surgical robot for colon resection, and the new funds will go toward manufacturing and clinical trials leading to FDA approval.
CellMax Life published results from a study showing its circulating tumor cell blood test accurately detected colorectal cancer and precancerous lesions at an 87 percent and 77 percent accuracy rate, respectively.
GI Supply launched the Spot Ex Endoscopic Tattoo to help gastroenterologists and surgeons fight colon cancer.
Israeli company RedHill Biopharma released final results from the Phase II clinical study of Bekinda for the treatment of diarrhea-predominant irritable bowel syndrome.
Results from TiGenix's phase III Admire-CD trial for Cx601, a perianal fistulas treatment for Crohn's disease patients, were published in Gastroenterology.
Medical diagnostic company Check-Cap received a CE mark for C-Scan, an ingestible capsule for preparation-free colorectal cancer screening.
GMed, a Modernizing Medicine company, named gastroenterologist Arnold Levy, MD, one of its gastroenterology EMR strategic advisors.
Abivax, a biotechnology company, is beginning an extension study concerning ABX464-102, its ulcerative colitis therapy, to evaluate the drug's safety and efficacy.